Zikan M, Pohlreich P, Stribrna J
Department of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, U Nemocnice 5, 12853 Prague 2, Czech Republic.
J Genet. 2005 Apr;84(1):63-7. doi: 10.1007/BF02715891.
Ovarian cancer is one of the most severe of oncological diseases. Inherited mutations in cancer susceptibility genes play a causal role in 5-10% of newly diagnosed tumours. BRCA1 and BRCA2 gene alterations are found in the majority of these cases. The aim of this study was to analyse the BRCA1 gene in the ovarian cancer risk group to characterize the spectrum of its mutations in the Czech Republic. Five overlapping fragments amplified on both genomic DNA and cDNA were used to screen for the whole protein-coding sequence of the BRCA1 gene. These fragments were analysed by the protein truncation test (PTT) and direct sequencing. Three inactivating mutations were identified in the group of 30 Czech ovarian cancer patients: the 5382insC mutation in two unrelated patients and a deletion of exons 21 and 22 in another patient. In addition, we have found an alternatively spliced product lacking exon 5 in two other unrelated patients. The 5382insC is the most frequent alteration of the BRCA1 gene in Central and Eastern Europe. The deletion of exons 21 and 22 affects the BRCT functional domain of the BRCA1 protein. Although large genomic rearragements are known to be relatively frequent in Western European populations, no analyses have been performed in our region yet.
卵巢癌是最严重的肿瘤疾病之一。癌症易感基因的遗传性突变在5% - 10%新诊断的肿瘤中起因果作用。在大多数这些病例中发现了BRCA1和BRCA2基因改变。本研究的目的是分析卵巢癌风险组中的BRCA1基因,以确定其在捷克共和国的突变谱。在基因组DNA和cDNA上扩增的五个重叠片段用于筛选BRCA1基因的整个蛋白质编码序列。这些片段通过蛋白质截短试验(PTT)和直接测序进行分析。在30名捷克卵巢癌患者组中鉴定出三个失活突变:两名无关患者中的5382insC突变,以及另一名患者中外显子21和22的缺失。此外,我们在另外两名无关患者中发现了一种缺少外显子5的可变剪接产物。5382insC是中东欧BRCA1基因最常见的改变。外显子21和22的缺失影响BRCA1蛋白的BRCT功能域。虽然已知大的基因组重排在西欧人群中相对频繁,但我们地区尚未进行分析。